Abstract: This invention relates to antibodies that bind to and inhibit the activity of glial cell-derived neurotrophic factor family receptor alpha like (GFRAL) protein. The invention also relates to the GDF15-GFRAL signalling pathway as a therapeutic target for states of cachexia and conditions involving reduction in food intake and reduction in muscle and fat mass.
| # | Name | Date |
|---|---|---|
| 1 | 202317072310-TRANSLATIOIN OF PRIOIRTY DOCUMENTS ETC. [23-10-2023(online)].pdf | 2023-10-23 |
| 2 | 202317072310-STATEMENT OF UNDERTAKING (FORM 3) [23-10-2023(online)].pdf | 2023-10-23 |
| 3 | 202317072310-Sequence Listing in txt [23-10-2023(online)].txt | 2023-10-23 |
| 4 | 202317072310-Sequence Listing in PDF [23-10-2023(online)].pdf | 2023-10-23 |
| 5 | 202317072310-FORM 1 [23-10-2023(online)].pdf | 2023-10-23 |
| 6 | 202317072310-DRAWINGS [23-10-2023(online)].pdf | 2023-10-23 |
| 7 | 202317072310-DECLARATION OF INVENTORSHIP (FORM 5) [23-10-2023(online)].pdf | 2023-10-23 |
| 8 | 202317072310-COMPLETE SPECIFICATION [23-10-2023(online)].pdf | 2023-10-23 |
| 9 | 202317072310-FORM-26 [01-01-2024(online)].pdf | 2024-01-01 |
| 10 | 202317072310-Proof of Right [29-03-2024(online)].pdf | 2024-03-29 |
| 11 | 202317072310-FORM-26 [29-03-2024(online)].pdf | 2024-03-29 |
| 12 | 202317072310-FORM 3 [29-03-2024(online)].pdf | 2024-03-29 |
| 13 | 202317072310-FORM 18 [05-02-2025(online)].pdf | 2025-02-05 |